CRESCENT BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
CRESCENT BIOPHARMA, INC. (CBIO) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price of $8.51 per share as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice · last filed 2026-07-30
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $8.51.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $7.08.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $6.26.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $6.20.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $8.51 10-Q · filed 2026-07-30 |
| 2026-03-31 | $7.08 10-Q · filed 2026-04-29 |
| 2025-12-31 | $6.26 10-K · filed 2026-02-26 |
| 2025-09-30 | $6.20 10-Q · filed 2025-11-06 |
| 2025-06-30 | $6.16 10-Q · filed 2025-07-31 |
| 2025-03-31 | $5.16 10-Q · filed 2025-05-14 |
| 2021-06-30 | $2.06 10-Q · filed 2021-08-05 |
| 2021-03-31 | $2.06 10-Q · filed 2021-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |